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Background: A high prevalence of hypogonadism among men with type 2 diabetes mellitus (T2DM) has been reported
worldwide. This in turn creates a substantial public health burden in terms of inadequate sexual function and potential
infertility. However, the status of this health problem is not well established in Ethiopia. Therefore, this study was aimed to
assess hypogonadism and its associated risk factors among men with T2DM.
Methods: This cross-sectional study was conducted at Tikur Anbesa Specialized Teaching Hospital in Addis Ababa, Ethiopia from
February to May 2017 on 115 male patients with T2DM aged 40–80 years. Symptoms of hypogonadism were assessed using the
Androgen Deficiency in Aging Men (ADAM) questionnaire. Total testosterone (TT), luteinising hormone (LH) and follicle
stimulating hormone (FSH), fasting blood glucose (FBG) and lipid profiles were measured at the clinical chemistry laboratory
of Ethiopian Public Health Institute. Hypogonadism was defined as the presence of clinical symptoms and low TT [TT <
12.1 nmol/l] according to International Society for the Study of the Aging Male.
Results: Of the total 115 study subjects, hypogonadism was seen in 23.5%, of whom 74.1% and 25.9% had secondary and
primary hypogonadism, respectively. TT showed a significant negative correlation with waist circumference (WC) (r =−0.465,
p < 0.001), BMI (r =−0.363; p < 0.001), FBG (rho =−0.328, p < 0.001) and TG (rho =−0.357, p < 0.001) respectively but a
significant positive correlation with HDL-C (r = 0.339, p < 0.001)]. WC and FBG were independently associated with
hypogonadism.
Conclusion: According to our study, visceral obesity and hyperglycaemia were found to be independent risk factors associated
with hypogonadism.
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Introduction
Hypogonadism has been defined as the presence of low serum
testosterone levels and clinical symptoms such as erectile dys-
function (ED), diminished frequency of morning erections,
decrease in sexual thoughts (low libido), difficulty in achieving
orgasm, reduced intensity of orgasm, fatigue, impotence,
impaired concentration, depression and decreased sense of
well-being.1–3 The total testosterone (TT) or free testosterone
cut-off values used in the definition varies according to different
guidelines. For instance, an Endocrine Society Clinical Practice
guideline recommended 10.4 nmol/l1 and the International
Society for the Study of the Aging Male recently recommended
12.1 nmol/l as a lower TT cut-off value.3
The linkage between hypogonadism and type 2 diabetes (T2DM)
has recently been drawing public health attention.4 This is
because male patients with T2DM are significantly more likely
to develop hypogonadism.1,4,5 As a result of this and the rise
in the prevalence of T2DM, a high prevalence (20–64%) of hypo-
gonadism has been reported worldwide.5 Consequently, sexual
function problems, infertility and poor quality of life are becom-
ing prevalent among these patients.4
Hypogonadism was classified as primary (hypergonadotropic)
and secondary (hypogonadotropic) hypogonadism. Primary
hypogonadism, which is caused by testicular failure, is
characterised by high luteinising (LH) and follicle stimulating
hormone (FSH) concentrations whereas secondary hypogonad-
ism, which is caused by the defect in the hypothalamus or pitu-
itary gland, is characterised by low or low-normal FSH and LH.
Both types of hypogonadism were observed in men with
T2DM. However, secondary hypogonadism was the most preva-
lent among these men with a prevalence range of 25–40%.2,4
The exact mechanism of the occurrence of hypogonadism in
men with T2DM remains unclear, but insulin resistance, an
important feature of T2DM, appears to be a common denomi-
nator. This can be supported by the fact that testosterone repla-
cement therapy (TRT) for hypogonadal men with T2DM was
found to improve insulin sensitivity.6 More importantly, obesity
appears to play an important synergistic role in this
pathogenesis.4,6
Because an increase in fat mass in adipose tissue can cause an
increase in the activity of the aromatase enzyme, this can
convert serum testosterone to oestradiol, which directly reduces
the level of serum testosterone. The resulting oestradiol provides
negative feedback on the hypothalamic–pituitary–gonadal axis,
and further reduces the level of serum testosterone.2
Different studies have identified that waist circumference (WC),
body mass index (BMI), hyperglycaemia and dyslipidaemia in
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male patients with T2DM were found to be major risk factor cor-
relates of T2DM associated closely with hypogonadism.7,8 The
association of some of these correlates with TT can be indirectly
explained as testosterone replacement therapy (TRT) was found
to alter them. It was confirmed that a significant decrease in WC
was observed in men with new onset T2DM treated with trans-
dermal testosterone, diet and exercise compared with those pre-
scribed only diet and exercise. TRT was also found to decrease
triglycerides (TG), total cholesterol (TC) and low-density lipopro-
tein cholesterol (LDL-C) and improved glycaemic controls but its
action on high-density lipoprotein cholesterol (HDL-C) was
inconsistent.4,6
As the incidence of T2DM is steadily rising in men worldwide,
T2DM related hypogonadism has also been rising at an alarming
rate. This, in turn, creates a substantial public health burden in
terms of inadequate sexual function and potential infertility in
men.9 However, this condition is often under-diagnosed and
under-discussed in developing countries. Different reasons
were suggested to explain this fact. First, patients make such
conversation personal and feel uncomfortable about initiating
it due to taboo or stigma.10 Second, the target-based manage-
ment of T2DM is already creating a workload for clinicians and
as a result they do not usually engage in diagnosing and treating
hypogonadism in these patients.11 Third, a testosterone test,
which is used to identify those who can benefit from TRT and
treated with phosphodiesterase inhibitors to improve ED, is
not routinely done in resource-limited countries like Ethio-
pia.11,12 Fourth, even though the Endocrine Society task force
and the International Society for the Study of Aging Male rec-
ommended physicians order a testosterone test for all men
with T2DM, physicians do not usually order the test to diagnose
this condition.1,3
Moreover, despite the continent having a high burden of T2DM,
hypogonadism is rarely studied in sub-Saharan African countries
and Ethiopia is no exception. Therefore, we aimed to determine
the prevalence and associated factors of male hypogonadism in
men with T2DM.
Study design and methods
This cross-sectional study was conducted in the Diabetic Clinic of
Tikur Anbessa Specialized Teaching Hospital in Addis Ababa,
Ethiopia from February to May 2017. A total of 115 with T2DM
whose age was between 40 and 80 years were selected using a
convenience samplingmethod among consecutivemalepatients
who were already diagnosed with T2DM and waiting for treat-
ment during the study period. Their diagnosis of T2DM was
obtained from their medical records. With the help of a physician,
any subjects with a history of chronic diseases including end-
stage renal failure, hypopituitarism, acquired immunodeficiency
syndrome, and malignancy were excluded from the study as
these conditions are known to decrease testosterone level.
The study protocol was approved by the Departmental Research
and Ethics Review Committee of the Department of Medical Lab-
oratory Sciences and that of Internal Medicine of the College of
Health Sciences of Addis Ababa University. All the selected sub-
jects gave written informed consent.
Demographic and clinical assessment
Demographic characteristics such as age, marital status and
smoking history were collected using a structured questionnaire.
Duration of diabetes and current diabetic medication were col-
lected from medical records using checklists.
Data for body mass index (BMI) and waist circumference (WC)
were collected and interpreted according to the consensus
statement from the International Diabetes Federation and the
blood pressure of each subject was measured by an experienced
nurse after the patient was allowed to rest for about 10 minutes.
Subjects whose BP readings were ≥ 140/90 mmHg were con-
sidered hypertensive.13
Symptoms of hypogonadism were assessed using the ADAM14
questionnaire, which is the most widely accepted screening
questionnaire consisting of 10 questions. Subjects who can
read and write completed the ADAM questionnaire on their
own, and those who could not were assisted by an experienced
nurse. A diagnosis of ADAM was suspected if a ‘yes’ answer was
provided to questions 1 (presence of loss of libido) and 7 (pres-
ence of erectile dysfunction), or to any other three questions. To
make the questionnaire understood, it was translated into
Amharic (the local working language).
Laboratory evaluation
Five millilitres of overnight fasting venous blood sample was col-
lected via sterile venepuncture from each study subject before
10 am in a serum separator tube (BDTM). Then, each sample of
blood was allowed to clot for 30 minutes and centrifuged at
3000 revolutions per minutes for 5 minutes to separate the
serum. The separated serum samples were stored at −20°C
until analysis. Analysis was done at the Ethiopian public health
clinical chemistry laboratory using an automated analyser
(Elecsys® 2010 analyzer-Cobas e 411, Roche Diagnostics GmbH,
Indianapolis, IN, USA), which uses electrochemiluminescence
(ECL) technology to determine hormones (TT, LH and FSH). To
measure TT using this analyser, the competitive immunoassay
principle with analyte liberation was used and to measure
both LH and FSH the sandwich immunoassay principle was
used. To determine lipid profiles (using Cobas 6000 module-
501, Roche Diagnostics GmbH, Indianapolis, IN, USA), the enzy-
matic method was used. To determine fasting blood glucose
(FBG) level using glucose oxidase method, an automated analy-
ser (Mindray 200E, Guandog, China) was used.
Hypogonadism was defined as the presence of symptoms of
hypogonadism and TT (≤ 12.1 nmol/l). Though a different TT
cut-off value was recommended by different guidelines, the
indicated cut-off value used is a recent recommendation in
2015 by the International Society for the Study of the
Aging Male.3 Hypogonadal subjects were further classified.
Subjects who had hypogonadism with either low or normal
FSH (≤ 14 mIU/ml), LH (≤ 7.8 mIU/ml) or both were diagnosed
as having secondary hypogonadism whereas those with
higher serum FSH (> 14 mIU/ml), LH (> 7.8 mIU/ml) or both
were diagnosed as having primary hypogonadism.15
Hypercholesterolemia was indicated by a total cholesterol
level ≥ 200 mg/dl. HDL-C was considered low when the level
was < 40 mg/dl. LDL-C was considered high when the level
was ≥1 00 mg/dl. Hypertriglyceridemia was considered high
when the TG level was ≥ 150 mg/dl. Dyslipidaemia was con-
sidered present when one or more of the previous abnormalities
were found in serum lipids.13
Statistical analysis
Data obtained were entered into Microsoft Excel (Microsoft
Corp, Redmond, WA, USA) and exported to SPSS version 20
(IBM Corp, Armonk, NY, USA) for analysis. Descriptive statistics
were used to summarise qualitative variables. All parametric
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male patients with T2DM were found to be major risk factor cor-
relates of T2DM associated closely with hypogonadism.7,8 The
association of some of these correlates with TT can be indirectly
explained as testosterone replacement therapy (TRT) was found
to alter them. It was confirmed that a significant decrease in WC
was observed in men with new onset T2DM treated with trans-
dermal testosterone, diet and exercise compared with those pre-
scribed only diet and exercise. TRT was also found to decrease
triglycerides (TG), total cholesterol (TC) and low-density lipopro-
tein cholesterol (LDL-C) and improved glycaemic controls but its
action on high-density lipoprotein cholesterol (HDL-C) was
inconsistent.4,6
As the incidence of T2DM is steadily rising in men worldwide,
T2DM related hypogonadism has also been rising at an alarming
rate. This, in turn, creates a substantial public health burden in
terms of inadequate sexual function and potential infertility in
men.9 However, this condition is often under-diagnosed and
under-discussed in developing countries. Different reasons
were suggested to explain this fact. First, patients make such
conversation personal and feel uncomfortable about initiating
it due to taboo or stigma.10 Second, the target-based manage-
ment of T2DM is already creating a workload for clinicians and
as a result they do not usually engage in diagnosing and treating
hypogonadism in these patients.11 Third, a testosterone test,
which is used to identify those who can benefit from TRT and
treated with phosphodiesterase inhibitors to improve ED, is
not routinely done in resource-limited countries like Ethio-
pia.11,12 Fourth, even though the Endocrine Society task force
and the International Society for the Study of Aging Male rec-
ommended physicians order a testosterone test for all men
with T2DM, physicians do not usually order the test to diagnose
this condition.1,3
Moreover, despite the continent having a high burden of T2DM,
hypogonadism is rarely studied in sub-Saharan African countries
and Ethiopia is no exception. Therefore, we aimed to determine
the prevalence and associated factors of male hypogonadism in
men with T2DM.
Study design and methods
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convenience samplingmethod among consecutivemalepatients
who were already diagnosed with T2DM and waiting for treat-
ment during the study period. Their diagnosis of T2DM was
obtained from their medical records. With the help of a physician,
any subjects with a history of chronic diseases including end-
stage renal failure, hypopituitarism, acquired immunodeficiency
syndrome, and malignancy were excluded from the study as
these conditions are known to decrease testosterone level.
The study protocol was approved by the Departmental Research
and Ethics Review Committee of the Department of Medical Lab-
oratory Sciences and that of Internal Medicine of the College of
Health Sciences of Addis Ababa University. All the selected sub-
jects gave written informed consent.
Demographic and clinical assessment
Demographic characteristics such as age, marital status and
smoking history were collected using a structured questionnaire.
Duration of diabetes and current diabetic medication were col-
lected from medical records using checklists.
Data for body mass index (BMI) and waist circumference (WC)
were collected and interpreted according to the consensus
statement from the International Diabetes Federation and the
blood pressure of each subject was measured by an experienced
nurse after the patient was allowed to rest for about 10 minutes.
Subjects whose BP readings were ≥ 140/90 mmHg were con-
sidered hypertensive.13
Symptoms of hypogonadism were assessed using the ADAM14
questionnaire, which is the most widely accepted screening
questionnaire consisting of 10 questions. Subjects who can
read and write completed the ADAM questionnaire on their
own, and those who could not were assisted by an experienced
nurse. A diagnosis of ADAM was suspected if a ‘yes’ answer was
provided to questions 1 (presence of loss of libido) and 7 (pres-
ence of erectile dysfunction), or to any other three questions. To
make the questionnaire understood, it was translated into
Amharic (the local working language).
Laboratory evaluation
Five millilitres of overnight fasting venous blood sample was col-
lected via sterile venepuncture from each study subject before
10 am in a serum separator tube (BDTM). Then, each sample of
blood was allowed to clot for 30 minutes and centrifuged at
3000 revolutions per minutes for 5 minutes to separate the
serum. The separated serum samples were stored at −20°C
until analysis. Analysis was done at the Ethiopian public health
clinical chemistry laboratory using an automated analyser
(Elecsys® 2010 analyzer-Cobas e 411, Roche Diagnostics GmbH,
Indianapolis, IN, USA), which uses electrochemiluminescence
(ECL) technology to determine hormones (TT, LH and FSH). To
measure TT using this analyser, the competitive immunoassay
principle with analyte liberation was used and to measure
both LH and FSH the sandwich immunoassay principle was
used. To determine lipid profiles (using Cobas 6000 module-
501, Roche Diagnostics GmbH, Indianapolis, IN, USA), the enzy-
matic method was used. To determine fasting blood glucose
(FBG) level using glucose oxidase method, an automated analy-
ser (Mindray 200E, Guandog, China) was used.
Hypogonadism was defined as the presence of symptoms of
hypogonadism and TT (≤ 12.1 nmol/l). Though a different TT
cut-off value was recommended by different guidelines, the
indicated cut-off value used is a recent recommendation in
2015 by the International Society for the Study of the
Aging Male.3 Hypogonadal subjects were further classified.
Subjects who had hypogonadism with either low or normal
FSH (≤ 14 mIU/ml), LH (≤ 7.8 mIU/ml) or both were diagnosed
as having secondary hypogonadism whereas those with
higher serum FSH (> 14 mIU/ml), LH (> 7.8 mIU/ml) or both
were diagnosed as having primary hypogonadism.15
Hypercholesterolemia was indicated by a total cholesterol
level ≥ 200 mg/dl. HDL-C was considered low when the level
was < 40 mg/dl. LDL-C was considered high when the level
was ≥1 00 mg/dl. Hypertriglyceridemia was considered high
when the TG level was ≥ 150 mg/dl. Dyslipidaemia was con-
sidered present when one or more of the previous abnormalities
were found in serum lipids.13
Statistical analysis
Data obtained were entered into Microsoft Excel (Microsoft
Corp, Redmond, WA, USA) and exported to SPSS version 20
(IBM Corp, Armonk, NY, USA) for analysis. Descriptive statistics
were used to summarise qualitative variables. All parametric
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values were expressed as mean ± SD but for non-parametric
values median was reported with interquartile range. Pearson’s
and Spearman’s correlation for parametric and non-parametric
data were used to establish correlations between dependent
and independent variables respectively. The Mann–Whitney U-
test was used for comparing non-parametric data and an inde-
pendent samples t-test for parametric data. Simple logistic
regression was used to identify potential predictors of hypogo-
nadism and those with a p-value < 0.25 were entered into a
multivariate model with automatic backward and forward likeli-
hood ratio method of elimination, based on the p-values in the
model to identify independent risk factors for hypogonadism. A
p-value < 0.05 was considered statistically significant.
Results
Sociodemographic and clinical characteristics of study
participants
As demonstrated in Table 1, of the total of 115 study subjects,
more than half of them were in the age range greater than 60
years (range 40–80 years). The median age of the study subjects
was 60 years (IQR 40–78.2). The mean ± SD of BMI and WC were
25.30 ± 3.26 kg/m2 and 98.56 ± 8.70 cm respectively. The
median (IQR) systolic and diastolic blood pressure were
130 mmHg (IQR 100–180) and 80 mmHg (IQR 60–100).
Regarding the current medication of diabetes, 54 (46.8%), 35
(30.4%), 21 (18.3%), and 4 (3.5%) were on insulin or on met-
formin, a combination of metformin and glibenclamide, a
combination of insulin and metformin, and glibenclamide
alone respectively. Moreover, 72 (62.7%) of the subjects
were found to be hypertensive and 91(79%) had
dyslipidaemia. The majority of the subjects (111; 96.5%)
were married and only 3 (2.6%) of them were divorced.
About 27% of the subjects were current or past smokers.
Laboratory measurements
As demonstrated in Table 2, themean ± SD of TT, LH and FSHwas
19.15 ± 6.99 nmol/l, 7.56 ± 3.30 mIU/l and 7.67 ± 4.94 mIU/l
respectively. The mean ± SD of HDL-C, LDL-C and TC was 35.19
± 10.44 mg/dl, 90.53 ± 32.46 mg/dl, and 72.2 ± 253.2 mg/dl
respectively. The median values of TG and FBG were 141.9 mg/
dl (IQR 71.07–656.65 mg/dl) and 168 mg/dl (IQR 82.9–307.2 mg/
dl) within 2.5th and 97.5th percentile values respectively.
Prevalence of androgen deficiency symptoms, low
testosterone level and secondary hypogonadism
among the study subjects
The Androgen Deficiency in the Aging Male (ADAM) question-
naire was used to assess symptoms of hypogonadism among
the study subjects. As summarised in Table 3, 104 (90.4%)
were ADAM positive whereas the remaining 11 (9.6%) were
ADAM negative. Only 27 (23. 5%) of ADAM positive subjects
had a low TT level (TT≤ 12.1 nmol) and hence were hypogona-
dal. It is important to note that about 66.9% of ADAM positive
patients had normal TT levels and this speaks to the low sensi-
tivity of the questionnaire.
Comparison of some clinical and laboratory
measurements between subjects with and without
hypogonadism
Paired t-test results are summarised in Table 4. Mean BMI
was significantly higher in the hypogonadal group (26.9 ±
Table 1: Sociodemographic and clinical characteristics of the study subjects (n = 115)
Variables Categories n (%) Mean ± SD Range Median (IQR)
Age (years) 59.6 ± 10.2 40–80 60 (40–78.2)
Marital status Married 111 (96.5)
Divorced 3 (2.6)
Widowed 1 (0.9)
Smoking history Current 5 (4.3)
Past 26 (22.6)
Never 84 (73)
Duration of DM 9 ± 6.9 1–30 7 (1–30)
Diabetes medication Insulin 27 (23.4)
Metformin 27 (23.4)
Glibenclamide 4 (3.5)
Insulin and metformin 21 (18.3)
Metformin and glibenclamide 35 (30.4)
Dyslipidaemia Yes 91 (79.1)
No 24 (20.9)
Hypertension Yes 72 (62.9)
No 43 (37.4)
BMI (kg/m2) Normal 59 (51.3) 25.30 ± 3.3 18.7–34.8
Overweight 46 (40.0)
Obese 10 (8.7)
WC (cm) Normal 30 (26.1) 98.56 ± 8.7 80–118
Obese 85 (73.9)
SBP (mmHg) 100–190 130 (100–180)
DBP (mmHg) 60–110 80 (60–100)
Note: BMI = body mass index; WC = waist circumference; SBP = systolic blood pressure; DBP = diastolic blood pressure; IQR = interquartile range.
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3.5 kg/m2) than in eugonadal individuals (24.86 ± 3.02 kg/m2),
t (113) = 3.035, p = 0.003. The mean WC was significantly
higher in the hypogonadal group (104.85 ± 8.77 cm) than in
eugonadal individuals (96.62 ± 7.75 cm), t (113) = 4.676, p <
0.001. Similarly, the mean FSH level was significantly lower
in the hypogonadal group (6.28 ± 2.75 mIU/ml) than in eugo-
nadal individuals (8.10 ± 5.38 mIU/ml), t (113) =−2.34, p =
0.022. However, the mean HDL-C level was lower in the
hypogonadal group (31.08 ± 8.57 mg.57 mg/dl) than in the
eugonadal group (36.83 ± 10.63 mg.63 mg/dl) t (113) =
−2.563, p = 0.012
A Mann–Whitney U-test indicated that the FBG level was signifi-
cantly higher in the hypogonadal group with a median of
235 mg/dl than in the eugonadal group with a median of
161 mg/dl, U = 711.5, p = 0.002. Similarly, TG was significantly
elevated among the hypogonadal group with a median of
174 mg/dl than in the eugonadal ones with a median of
136 mg/dl.
Table 2: Laboratory measurement values of some parameters of men with T2DM attending for treatment at the diabetic clinic of TASTH February–March
2017 (n = 115)
Variables Categories n (%) Mean ± SD Range Median (IQR)
TT (nmol/l) ≤ 12.1 29 (25.2) 19.15 ± 6.99 6.97–37.13
> 12.1 86 (74.8)
LH (mIU/ml) > 7.8 43 (37. 4) 7.56 ± 3.30 2.71–18.7 7.07 (3.37–16.01)
< 7.8 72 (62.6)
FSH (mIU/ml) ≤ 14 102 (88.7) 7.68 ± 4.94 1.39–26.25
> 14 13 (11.3)
FBG (mg/dl) 82–313 168 (82.9–307.2)
TC (mg/dl) < 200 98 (85.2) 72.2–253.2 148 (84.1–244.8)
≥ 200 17 (14.8)
TG (mg/dl) < 150 64 (55.7) 59.4–776.4 142 (71.1–656.7)
≥ 150 51 (44.3)
LDH-C (mg/dl) < 100 70 (60.9) 90.53 ± 32.5 28.5–170.6
≥ 100 45 (39.1)
HDL-C (mg/dl) < 40 83 (72.2) 35.5 ± 10.4 13.3–71
≥ 40 32 (27.8)
Note: TT = total testosterone; LH = luteinising hormone; FSH = follicle stimulating hormone; TC = total cholesterol; FBG = fasting blood glucose; LDL-C = low-density lipo-
protein cholesterol; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides.
Table 3: Frequency of low and normal total testosterone groups in











ADAM positive 27 (23.5%) 77 (66.9%) 104
(90.4%)
ADAM negative 2 (1.7%) 9 (7.8%) 11
(9.6%)
Total 29 (25.2%) 86 (74.8%) 115
(100%)
Table 4: Comparison of some clinical and laboratory measurement values of study participants between hypogonadal and eugonadal groups (n = 115)
No. Parametric values
Testosterone level
t testHypogonadal group (n = 27) Eugonadal group (n = 88)
(mean ± SD) (mean ± SD) p-value
1 BMI (kg/m2) 26.90 ± 3.54 24.80 ± 3.02 0.003
2 WC (cm) 104.85 ± 8.77 96.62 ± 7.75 < 0.001
3 LH (mIU/ml) 7.06 ± 3.09 7.72 ± 3.36 0.365
4 FSH (mIU/ml) 6.28 ± 2.75 8.10 ± 5.38 0.022
5 TC (mg/dl) 159.37 ± 42.35 154.20 ± 38.28 0.549
6 LDL-C (mg/dl) 86.45 ± 36.09 91.78 ± 31.38 0.458
7 HDL-C (mg/dl) 31.08 ± 8.57 36.83 ± 10.63 0.012
No. Non-parametric values Median Median p-value
8 Age (years) 60.0 60.0 0.721
9 Duration of DM (years) 6.0 7.0 0.629
10 SBP (mmHg) 130.0 130.0 0.293
11 DBP (mmHg) 80.0 80.0 0.583
12 FBG (mg/dl) 235.0 161.0 0.002
13 TG (mg/dl) 174.0 136.0 0.047
Note: BMI = body mass index; WC = waist circumference; LH = luteinising hormone; FSH = follicle stimulating hormone; TC = total cholesterol; LDL-C = low-density lipo-
protein cholesterol; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides; SBP = systolic blood pressure; DSP = diastolic blood pressure.
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3.5 kg/m2) than in eugonadal individuals (24.86 ± 3.02 kg/m2),
t (113) = 3.035, p = 0.003. The mean WC was significantly
higher in the hypogonadal group (104.85 ± 8.77 cm) than in
eugonadal individuals (96.62 ± 7.75 cm), t (113) = 4.676, p <
0.001. Similarly, the mean FSH level was significantly lower
in the hypogonadal group (6.28 ± 2.75 mIU/ml) than in eugo-
nadal individuals (8.10 ± 5.38 mIU/ml), t (113) =−2.34, p =
0.022. However, the mean HDL-C level was lower in the
hypogonadal group (31.08 ± 8.57 mg.57 mg/dl) than in the
eugonadal group (36.83 ± 10.63 mg.63 mg/dl) t (113) =
−2.563, p = 0.012
A Mann–Whitney U-test indicated that the FBG level was signifi-
cantly higher in the hypogonadal group with a median of
235 mg/dl than in the eugonadal group with a median of
161 mg/dl, U = 711.5, p = 0.002. Similarly, TG was significantly
elevated among the hypogonadal group with a median of
174 mg/dl than in the eugonadal ones with a median of
136 mg/dl.
Table 2: Laboratory measurement values of some parameters of men with T2DM attending for treatment at the diabetic clinic of TASTH February–March
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Variables Categories n (%) Mean ± SD Range Median (IQR)
TT (nmol/l) ≤ 12.1 29 (25.2) 19.15 ± 6.99 6.97–37.13
> 12.1 86 (74.8)
LH (mIU/ml) > 7.8 43 (37. 4) 7.56 ± 3.30 2.71–18.7 7.07 (3.37–16.01)
< 7.8 72 (62.6)
FSH (mIU/ml) ≤ 14 102 (88.7) 7.68 ± 4.94 1.39–26.25
> 14 13 (11.3)
FBG (mg/dl) 82–313 168 (82.9–307.2)
TC (mg/dl) < 200 98 (85.2) 72.2–253.2 148 (84.1–244.8)
≥ 200 17 (14.8)
TG (mg/dl) < 150 64 (55.7) 59.4–776.4 142 (71.1–656.7)
≥ 150 51 (44.3)
LDH-C (mg/dl) < 100 70 (60.9) 90.53 ± 32.5 28.5–170.6
≥ 100 45 (39.1)
HDL-C (mg/dl) < 40 83 (72.2) 35.5 ± 10.4 13.3–71
≥ 40 32 (27.8)
Note: TT = total testosterone; LH = luteinising hormone; FSH = follicle stimulating hormone; TC = total cholesterol; FBG = fasting blood glucose; LDL-C = low-density lipo-
protein cholesterol; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides.
Table 3: Frequency of low and normal total testosterone groups in











ADAM positive 27 (23.5%) 77 (66.9%) 104
(90.4%)
ADAM negative 2 (1.7%) 9 (7.8%) 11
(9.6%)
Total 29 (25.2%) 86 (74.8%) 115
(100%)
Table 4: Comparison of some clinical and laboratory measurement values of study participants between hypogonadal and eugonadal groups (n = 115)
No. Parametric values
Testosterone level
t testHypogonadal group (n = 27) Eugonadal group (n = 88)
(mean ± SD) (mean ± SD) p-value
1 BMI (kg/m2) 26.90 ± 3.54 24.80 ± 3.02 0.003
2 WC (cm) 104.85 ± 8.77 96.62 ± 7.75 < 0.001
3 LH (mIU/ml) 7.06 ± 3.09 7.72 ± 3.36 0.365
4 FSH (mIU/ml) 6.28 ± 2.75 8.10 ± 5.38 0.022
5 TC (mg/dl) 159.37 ± 42.35 154.20 ± 38.28 0.549
6 LDL-C (mg/dl) 86.45 ± 36.09 91.78 ± 31.38 0.458
7 HDL-C (mg/dl) 31.08 ± 8.57 36.83 ± 10.63 0.012
No. Non-parametric values Median Median p-value
8 Age (years) 60.0 60.0 0.721
9 Duration of DM (years) 6.0 7.0 0.629
10 SBP (mmHg) 130.0 130.0 0.293
11 DBP (mmHg) 80.0 80.0 0.583
12 FBG (mg/dl) 235.0 161.0 0.002
13 TG (mg/dl) 174.0 136.0 0.047
Note: BMI = body mass index; WC = waist circumference; LH = luteinising hormone; FSH = follicle stimulating hormone; TC = total cholesterol; LDL-C = low-density lipo-
protein cholesterol; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides; SBP = systolic blood pressure; DSP = diastolic blood pressure.
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Correlation of total testosterone with independent
variables
As depicted in Table 5, TT showed significant negative
correlation with WC (r =−0.465, p < 0.001) and BMI (r = 0.363;
p < 0.001) respectively. TT also showed a significant negative
correlation with FBG (rho =−0.328, p < 0.001) and TG (rho =
−0.357, p < 0.001) respectively. However, it showed a significant
positive correlation with HDL-C (r = 0.339, p < 0.001). However,
age, duration of diabetes, LH, FSH, TC, LDL, SBP and DBP did
not show any correlation with TT.
Table 6 indicated that a 1 cm increase inWC increases the odds of
developing hypogonadism by 1.14 times, while controlling for
FBG. Similarly, an increase in FBG of 1 mg/dl increases the odds
of developing hypogonadism by 1.02 times while controlling
for WC.
Discussion
Prevalence of hypogonadism among the study subjects
In this study, the prevalence of symptoms of hypogonadism
was 90.4% using the ADAM questionnaire and this was unex-
pectedly high. However, only 23.5% of these individuals were
truly hypogonadal (TT ≤ 12.1 nmol/l). This discrepancy may
be partly due to the presentation of some testosterone
deficiency symptoms even when TT levels are as high as
15 nmol/l, which is different from the TT cut-off value
(12.1 nmol/l) used in our study.3 Additionally, the non-specific
nature of the ADAM questionnaire may also contribute to this
discrepancy because of the universal presence of these symp-
toms, even in patients with normal testosterone levels.
The prevalence of hypogonadism in this study was lower
than that of similar studies conducted in different
countries11,16–22 but a study conducted in Iran reported a
lower prevalence.23 Possible explanations for these variations
in the prevalence of hypogonadism in this population group
may be a variation in the type of testosterone measured,
whether TT or free testosterone, the cut-off value of TT or
free testosterone, age categories of the study subjects, the
prevalence of obesity, diabetic duration, study design and
laboratory methods used.5,24
In this study, 74.10% of hypogonadal subjects presented with
secondary hypogonadism and the remaining 25.9% presented
with primary hypogonadism. In line with our study, studies in
Nigeria and Jordan reported a similar higher prevalence of
these conditions.15,25 This finding confirmed the fact that sec-
ondary hypogonadism was more prevalent than primary hypo-
gonadism in men with T2DM. This was supported by the
evidence that insensitivity to insulin at the hypothalamic level
may contribute to a decrease in gonadotrophin releasing
hormone, which in turn decreases the level of gonadotropins.26
Correlation of serum total testosterone level with
independent variables
In this study, age was not significantly correlated with TT. This
variable also did not correlate with TT in similar studies con-
ducted in South Africa and New York.16,17 In contrast to this
study, a study conducted in Jordan reported a significant posi-
tive correlation of age with TT.25 Studies in England and Nigeria
reported the presence of a significant negative correlation
between age and TT level.12,15 The most plausible explanation
for these inconsistencies is that serum hormone binding globu-
lin (SHBG), which accounts for 60–80% of testosterone binding,
increases with age. Yet low levels of SHBG may occur in the
presence of insulin resistance, thus resulting in a decrease in
TT levels. Therefore, in the absence of the assessment of bioa-
vailable testosterone levels, the degree to which this confoun-
der (SHBG) affected our results if at all is difficult to speculate
on.27
This study also identified that BMI, WC, FBG and TG showed a
significant negative correlation with TT whereas HDL-C
showed a significant positive correlation with it. A case-
control study in Ghana reported a similar result.28 However,
the level of serum TT was not correlated with LH and FSH
in our study. This might be due to the slight rise in these hor-
mones with age, as observed in our study and others
suggesting an age-related alteration in this feedback
mechanism.17





1 BMI (kg/m2) −0.363 * < 0.001
2 WC (cm) −0.465 * < 0.001
3 LH (mIU/ml) 0.131 0.164
4 FSH (mIU/ml) 0.100 0.289
5 TC (mg/dl) −0.085 0.364
6 LDL (mg/dl) 0.051 0.488
7 HDL (mg/dl) 0.339 * < 0.001
No Parameters Spearman correlation
coefficient (rho)
p-value
8 Age (years) −0.015 0.874
9 Duration of DM (years) 0.047 0.616
10 SBP (mmHg) −0.154 0.100
11 DBP (mmHg) −0.124 0.185
12 FBG (mg/dl −0.328 * < 0.001
13 TG (mg/dl) −0.357 *< 0.001
Note: * = indicates significant correlation; rho = is used for non-parametric values; r
is used for parametric values; BMI = body mass index; WC = waist circumference;
LH = luteinising hormone; FSH = follicle stimulating hormone; TC = total choles-
terol; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipopro-
tein cholesterol; TG = triglycerides; SBP = systolic blood pressure; DSP = diastolic
blood pressure.
Table 6. Multiple logistic regression analyses: results of predictors of hypogonadism in males with T2DM (n = 115)
Variables B SE Wald p-value Odds ratio
95% CI for EXP (B)
Lower Upper
WC 0.154 0.038 16.484 0.000 1.20 1.08 1.256
FBG 0.015 0.004 11.774 0.001 1.02 1.01 1.024
Constant −19.614 4.294 20.863 0.000 0.000
Note: WC = waist circumference; FBG = fasting blood glucose.
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Comparison of independent variables in hypogonadal
and eugonadal groups of study subjects
In this study, age,DMduration, LH, FSH, LDL-C andTCdid not differ
significantly between hypogonadal and eugonadal groups. A
similar study conducted in Egypt also reported that there is no sig-
nificant mean difference in these variables between the two
groups except for the mean of lipid profiles, which showed a sig-
nificant difference between the two groups.22 It was unexpected
to see a lack of significant mean difference in LH and FSH
between the groups. This might be due to the high prevalence
of primary hypogonadism (25.9%) in our study, which is related
to testicular problems rather than to gonadotropins.
This study also identified that the means of WC, BMI, FBG or TG
were significantly higher in hypogonadal group but HDL-C was
significantly lower in this group. A similar study conducted in
Italy reported the same finding.28 However, the means of FBG,
TG or HDL-C did not show any statistically significant difference
between the two groups in a study conducted in China.7
Risk factors associated with hypogonadism
Though not to a great extent, WC and FBG were identified as risk
factors associated with hypogonadism in T2DM patients. Similar
studies also reported the same finding with regard to WC.7,8 The
finding of WC as a risk factor for hypogonadism was explained in
certain literature. First, it was suggested that visceral adiposity,
which is measured by WC, induces aromatisation of testosterone
to oestradiol and causes elevation of oestradiol primarily in
adipose tissue by aromatase, which has increased activity as
visceral adiposity increases.13 Oestradiol directly feeds back
and inhibits the hypothalamic–pituitary–testicular (HPG) axis
through kisspeptin.29 An increase in oestradiol levels would
also lead to the suppression of gonadotrophin-releasing
hormone and impaired secretion of gonadotropin by the pitu-
itary gland, which results in the reduction of testosterone
secretions.5,9 Second, an increase in adipocytokines due to
obesity, including the pro-inflammatory cytokines such as
tumour necrosis factor α (TNF-α), interleukin-1β, and interleu-
kin-6, inhibits the secretion of testosterone, both at the hypo-
thalamic–pituitary and the testicular level.30 Third, leptin
usually stimulates the release of gonadotropin-releasing
hormone; however, in obesity, where excess leptin is produced
from adipocytes, the hypothalamic–pituitary axis becomes
resistant to leptin. In addition, leptin inhibits the stimulatory
action of gonadotropin on the Leydig cells of testes, thereby
further decreasing testosterone production.31 Visceral adiposity
also enhances delivery of free fatty acids, which in turn
decreases peripheral glucose disposal primarily in skeletal
muscle and this results in hyperglycaemia.22 Hyperglycaemia
in turn has an effect on testicular microvasculature and results
in a decrease in TT level.32 Our finding regarding FBG as a risk
factor was not supported by much of the literature but is in
line with studies conducted in Ghana and Korea. This can be jus-
tified based on the fact that hyperglycaemia has an effect on tes-
ticular microvasculature by altering Leydig cell function, directly
causing primary hypogonadism. Moreover, if glucose is not
reaching the cells because of insulin insensitivity, there will
not be enough energy generated for the various metabolic pro-
cesses involved in maintaining testosterone levels.23,32
The present study has several limitations. One of these was the
use of a small, non-probability sampling method and the selec-
tion of study subjects from tertiary referral outpatient services,
where most of the patients had many complications and numer-
ous comorbidities. The absence of a control group (non-diabetic
subjects) to compare the prevalence of hypogonadism and
other variables in men with T2DM and cross-sectional nature
of this study was another limitation. Moreover, free testosterone
(FT) or bioavailable testosterone, which is the gold standard, and
preferable tests to diagnose hypogonadism in T2DM subjects
were not determined due to unavailability of these assays in
our practice. Additionally, failure to measure haemoglobin
A1C, which is a better glycaemic control indicator, because of
financial problems was a further limitation of this study. These
limitations made this study difficult to generalise to the majority
of men with T2DM.
Conclusion
In conclusion, this study demonstrated that hypogonadism is a
common occurrence among men with type 2 diabetes and
the most prevalent type of hypogonadism is hypogonadotropic
hypogonadism (secondary hypogonadism) in a tertiary health-
care setting in Addis Ababa, Ethiopia. Symptoms of hypogonad-
ism are, however, non-specific and occur in a significant
proportion of eugonadal subjects with normal testosterone.
This study also identified that visceral obesity and hyperglycae-
mia are independent risk factors for hypogonadism for Ethiopian
men with T2DM in a tertiary setting.
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